drugset
Drugs / GBS-NN/NN2
last change Jun 2025 re-read 2 minutes ago

GBS-NN/NN2

also known as GBS-NN

Vaccine

Developed for
group B streptococcal infection · meningitis · neonatal sepsis · pneumonia · primary bacterial infectious disease
Investigated by
Minervax ApS · European and Developing Countries Clinical Trials Partnership (EDCTP) · IQVIA Pty Ltd · Larix A/S · Simbec Research

Trials 7 · a red edge is where a trial was stopped

today NCT06592586 · Ph 2/3 NCT06494475 · Ph 2/3 NCT05782179 · Ph 1 NCT05154578 · Ph 2 NCT05005247 · Ph 1 NCT04596878 · Ph 2 NCT03807245 · Ph 1
20192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT05782179 Mar → Dec 2023 group B streptococcal infection Minervax ApS Completed No outcome recorded
Phase 1 NCT05005247 Aug 2021 → Aug 2022 group B streptococcal infection Minervax ApS Completed No outcome recorded
Phase 1 NCT03807245 Jan → Oct 2019 group B streptococcal infection Minervax ApS Completed No outcome recorded
Phase 22 trials
Phase 2 NCT05154578 Feb 2022 → Apr 2023 group B streptococcal infection Minervax ApS Completed No outcome recorded
Phase 2 NCT04596878 Nov 2020 → May 2022 group B streptococcal infection Minervax ApS Completed No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT06592586 Mar 2025 → Jun 2029 expected group B streptococcal infection, meningitis, neonatal sepsis, pneumonia +1 Minervax ApS Active not recruiting No outcome recorded
Phase 2/3 NCT06494475 Dec 2024 → Jun 2025 overdue group B streptococcal infection Minervax ApS Not yet recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02459262 Comparator May 2015 → Apr 2017 group B streptococcal infection Minervax ApS Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as GBS-NN/NN2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05005247 ↗
6

NCT03807245 ↗

NCT04596878 ↗

NCT06592586 ↗

NCT05782179 ↗

NCT05154578 ↗

NCT06494475 ↗
Known as GBS-NN ClinicalTrials.gov intervention name — accepted as the source's own label NCT02459262 ↗
Modality Vaccine “Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus” PMID 34215454 ↗ Jun 2021
Route Intramuscular “GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart” NCT03807245 ↗